Brief Article
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 7, 2011; 17(9): 1227-1233
Published online Mar 7, 2011. doi: 10.3748/wjg.v17.i9.1227
TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: A meta-analysis
De-Ke Jiang, Lei Yao, Wen-Zhang Wang, Bo Peng, Wei-Hua Ren, Xian-Mei Yang, Long Yu
De-Ke Jiang, Lei Yao, Wen-Zhang Wang, Bo Peng, Wei-Hua Ren, Xian-Mei Yang, The State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200433, China
Long Yu, The State Key Laboratory of Genetic Engineering, Institute of Biomedical Science, Fudan University, Shanghai 200433, China
Author contributions: Yu L designed the study; Jiang DK and Yao L performed the majority of the study and wrote the manuscript; Wang WZ, Peng B, Ren WH and Yang XM edited the manuscript.
Supported by the National 973 Program of China (No. 2004CB518605), the National 863 Project of China (No.2006AA020501), the National Key Sci-Tech Special Project of China (No.2008ZX10002-020), the Project of the Shanghai Municipal Science and Technology Commission (03dz14086) and the National Natural Science Foundation of China (No.30024001and 30771188)
Correspondence to: Long Yu, MD, PhD, The State Key Laboratory of Genetic Engineering, Institute of Biomedical Science, Fudan University, 220 Handan Road, Shanghai 200433, China. longyu@fudan.edu.cn
Telephone: +86-21-65643954 Fax: +86-21-65643250
Received: May 14, 2010
Revised: August 17, 2010
Accepted: August 24, 2010
Published online: March 7, 2011
Abstract

AIM: To investigate the association between TP53 Arg72Pro polymorphism and esophageal cancer (EC) risk using meta-analysis.

METHODS: All eligible studies published before March 1, 2010 were selected by searching PubMed using keywords “p53” or “TP53”, “polymorphism” or “variation”, “esophageal” and “cancer” or “carcinoma”. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were assessed for EC risk associated with TP53 Arg72Pro polymorphism using fixed- and random-effects models.

RESULTS: Nine case-control studies involving 5545 subjects were included in this meta-analysis. Significantly reduced risk of EC was associated with TP53 genotypes for Arg/Arg + Arg/Pro vs Pro/Pro (OR = 0.73, 95% CI: 0.57-0.94, P = 0.014). Subgroup analyses according to the source of controls and the specimens used for determining TP53 Arg72Pro genotypes or sample size showed that significantly reduced risk was observed only in studies which have population-based controls (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.66, P < 0.001), and use white blood cells or normal tissue to assess TP53 genotypes of cases (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.65, P < 0.001) or include at least 200 subjects (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.65, P < 0.001). Analysis restricted to well-designed studies also supported the significantly decreased risk of EC (Arg/Arg vs Pro/Pro: OR = 0.54, 95% CI: 0.46-0.64, P < 0.001).

CONCLUSION: TP53 Arg72 carriers are significantly associated with decreased EC risk. Nevertheless, more well-designed studies are needed to confirm our findings.

Keywords: TP53; Codon 72; Polymorphism; Esophageal cancer; Meta-analysis